Figueiredo Moreira Carolina Ferraz, Ferreira Peres Wilza Arantes, Silva do Nascimento Braga Juliana, Proença da Fonseca Ana Carolina, Junior Mario Campos, Luescher Jorge, Campos Ludmila, de Carvalho Padilha Patricia
Martagão Gesteira Institute of Childcare and Pediatrics (IPPMG) - Federal University of Rio de Janeiro (UFRJ), Brazil; Josué de Castro Nutrition Institute (INJC/UFRJ), Brazil.
Josué de Castro Nutrition Institute (INJC/UFRJ), Brazil.
Diabetes Res Clin Pract. 2025 Jun;224:112210. doi: 10.1016/j.diabres.2025.112210. Epub 2025 May 2.
To evaluate the effect of vitamin D supplementation on vitamin D deficiency (VDD) and glycemic control in children and adolescents with type 1 diabetes mellitus (T1DM).
This controlled clinical trial involved children and adolescents with T1DM for at least one year. Participants with VDD (25(OH)D < 30 ng/mL) were allocated to the intervention group and oral supplementation with cholecalciferol was prescribed at a dose of 2000 IU/day for 12 weeks. Sociodemographic, clinical, laboratory, lifestyle,anthropometric data and the Fok-I polymorphism (rs2228570) vitamin D receptor were collected. The effect of the intervention was assessed using Glass's Delta.
Of the 133 participants, 77.4 % were assigned to the intervention group (n = 103). Serum 25(OH)D concentration increased from 19.2 ± 6.2 to 30.9 ± 10.1 ng/mL (Glass's Delta = 1.2; CI 0.8/-1.4).A minimal effect was showed on glycemic control (Glass's Delta = 0.1; CI -0.2/0.4). A higher dose of insulin (β = -4.6; CI -8.1/-1.1; p = 0.010) and a high BMI (β = -0.3; CI - 0.6/-0.01; p = 0.059) were associated with lower serum 25(OH)D concentration, and sedentary (β = 0.20; CI - 0.1/0.7; p = 0.004) associated with higher HbA1C after 12 weeks of supplementation.
Oral cholecalciferol supplementation was effective in correcting VDD. This study identified the minimal effect of this intervention on glycemic control.
评估补充维生素D对1型糖尿病（T1DM）儿童和青少年维生素D缺乏（VDD）及血糖控制的影响。
这项对照临床试验纳入了患T1DM至少一年的儿童和青少年。VDD（25羟维生素D<30 ng/mL）参与者被分配至干预组，给予口服胆钙化醇补充剂，剂量为2000 IU/天，持续12周。收集社会人口统计学、临床、实验室、生活方式、人体测量数据以及维生素D受体的Fok-I多态性（rs2228570）。使用格拉斯增量（Glass's Delta）评估干预效果。
133名参与者中，77.4%被分配至干预组（n = 103）。血清25（OH）D浓度从19.2±6.2 ng/mL增至30.9±10.1 ng/mL（格拉斯增量=1.2；95%置信区间0.8/-1.4）。对血糖控制显示出最小效应（格拉斯增量=0.1；95%置信区间-0.2/0.4）。较高剂量胰岛素（β=-4.6；95%置信区间-8.1/-1.1；p = 0.010）和较高体重指数（BMI）（β=-0.3；95%置信区间-0.6/-0.01；p = 0.059）与较低血清25（OH）D浓度相关，补充12周后久坐不动（β=0.20；95%置信区间-0.1/0.7；p = 0.004）与较高糖化血红蛋白（HbA1C）相关。
口服胆钙化醇补充剂可有效纠正VDD。本研究确定了该干预对血糖控制的最小效应。
